Business
Allergy Therapeutics (AGY): Record sales and a ...
Allergy Therapeutics (AGY): Record sales and a ....
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n \n\n\nHardman & Co Research\n\n\n\nHardman & Co Research: Allergy Therapeutics (AGY): Record sales and a COVID-19 wildcard20-Jul-2020 / 07:30 GMT/BST\n\n\nHardman & Co Research: Record sales and a COVID-19 wildcard\n\nAGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) is an ultra-short-course subcutaneous allergy immunotherapy (SCIT) platform, which continues to make strong market share gains in a competitive environment. Several products using the PQ platform are in late-stage development in order to move them to full registration under new EU and US regulations. Another reassuring trading update states that the company has hit new records and has the resources in place to fund its pending R&D investment programme required to get its products approved by the regulators.\n\nhttps://www.hardmanandco.com/research/corporate-research/record-sales-and-a-covid-19-wildcard/\n\nIf you are interested in meeting the company, you can register your interest by clicking on the above link\n\n\n To contact us:\n\n Hardman & Co35 New Broad StreetLondonEC2M 1NH\n\n www.hardmanandco.com\n\n Follow us on Twitter @HardmanandCo\n \n \n Contact:\n\n Martin Hall+44 20 7194 7622\n \n \n \n\n [email protected] \n \n Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.\n\nAbout Hardman & Co: For the past 25 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case. \n\nHardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259....